NASDAQ:KDNY - Chinook Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.71
  • Forecasted Upside: 108.92 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$15.18
▼ -0.82 (-5.13%)
1 month | 3 months | 12 months
Get New Chinook Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KDNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KDNY

Average Price Target: $31.71
▲ +108.92% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Chinook Therapeutics in the last 3 months. The average price target is $31.71, with a high forecast of $40.00 and a low forecast of $25.00. The average price target represents a 108.92% upside from the last price of $15.18.

Buy

The current consensus among 8 investment analysts is to buy stock in Chinook Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2021Bloom BurtonReiterated RatingBuy$40.00Low
3/22/2021Bloom BurtonReiterated RatingBuyHigh
1/6/2021WedbushInitiated CoverageOutperform$28.00N/A
12/9/2020Cantor FitzgeraldInitiated CoverageOverweight$31.00Low
11/16/2020HC WainwrightInitiated CoverageBuy$28.00High
11/2/2020Evercore ISIInitiated CoverageOutperform$32.00Medium
10/20/2020OppenheimerUpgradeMarket Perform ➝ Outperform$25.00High
10/7/2020SVB LeerinkInitiated CoverageOutperform$38.00High
10/6/2020William BlairReiterated RatingOutperformHigh
(Data available from 6/21/2016 forward)
Chinook Therapeutics logo
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $15.18
Low: $13.48
High: $16.30

50 Day Range

MA: $16.31
Low: $13.60
High: $18.98

52 Week Range

Now: $15.18
Low: $10.50
High: $21.68

Volume

2,264,500 shs

Average Volume

201,612 shs

Market Capitalization

$677.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Chinook Therapeutics?

The following Wall Street sell-side analysts have issued reports on Chinook Therapeutics in the last twelve months: Bloom Burton, Cantor Fitzgerald, Evercore ISI, HC Wainwright, Oppenheimer Holdings Inc., SVB Leerink LLC, Wedbush, William Blair, and Zacks Investment Research.
View the latest analyst ratings for KDNY.

What is the current price target for Chinook Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Chinook Therapeutics in the last year. Their average twelve-month price target is $31.71, suggesting a possible upside of 108.9%. Bloom Burton has the highest price target set, predicting KDNY will reach $40.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $25.00 for Chinook Therapeutics in the next year.
View the latest price targets for KDNY.

What is the current consensus analyst rating for Chinook Therapeutics?

Chinook Therapeutics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KDNY will outperform the market and that investors should add to their positions of Chinook Therapeutics.
View the latest ratings for KDNY.

What other companies compete with Chinook Therapeutics?

How do I contact Chinook Therapeutics' investor relations team?

Chinook Therapeutics' physical mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The company's listed phone number is 510-848-4400 and its investor relations email address is [email protected] The official website for Chinook Therapeutics is chinooktx.com.